ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near Philadelphia, PA, USA:

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

This is a Phase 3 Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hem...

Enrolling
Chronic Kidney Disease
Secondary Hyperparathyroidism
Drug: Etelcalcetide

Phase 3

Amgen
Amgen

Philadelphia, Pennsylvania, United States and 42 other locations

The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of...

Enrolling
Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)
Drug: Paricalcitol

Phase 3

AbbVie
AbbVie

Philadelphia, Pennsylvania, United States and 12 other locations

A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and a...

Enrolling
Chronic Kidney Disease (CKD)
Drug: REGN5458
Drug: REGN5459

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Philadelphia, Pennsylvania, United States and 8 other locations

New

and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...

Begins enrollment in 2 months
Chronic Kidney Disease and Hypertension
Drug: Baxdrostat/dapagliflozin
Drug: Placebo/dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Chester, Pennsylvania, United States and 319 other locations

To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...

Enrolling
Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease
Drug: Placebo
Drug: RGLS8429

Phase 1

Regulus Therapeutics

Bethlehem, Pennsylvania, United States of America and 27 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Active, not recruiting
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Pottstown, Pennsylvania, United States and 295 other locations

The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney ...

Enrolling
Autosomal Recessive Polycystic Kidney (ARPKD)
Drug: Tolvaptan Suspension
Drug: Tolvaptan Tablets

Phase 3

Otsuka
Otsuka

Philadelphia, Pennsylvania, United States and 27 other locations

CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney...

Enrolling
Kidney Insufficiency, Chronic
Chronic Kidney Diseases
Drug: TOUR006 - 25 MG
Drug: TOUR006 - 50 MG

Phase 2

Tourmaline Bio

Bethlehem, Pennsylvania, United States and 48 other locations

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

Phase 3

Bayer
Bayer

Philadelphia, Pennsylvania, United States and 338 other locations

percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with ...

Active, not recruiting
Chronic Kidney Diseases
Type 1 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)

Phase 2

Prokidney

Newark, Delaware, United States and 4 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems